Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.26M | 214.80K | -272.30K | -377.30K | -1.97M |
| Total Depreciation and Amortization | 18.30K | 16.60K | 18.10K | 19.50K | 25.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 181.00K | -1.32M | -1.23M | -1.19M | 60.60K |
| Change in Net Operating Assets | 122.70K | -1.04M | -664.60K | -467.00K | -98.80K |
| Cash from Operations | -937.70K | -2.12M | -2.15M | -2.01M | -1.98M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 124.50K | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -13.50K | 1.68M | 1.69M | 1.69M | 1.69M |
| Cash from Investing | 111.00K | 1.68M | 1.69M | 1.69M | 1.69M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 341.80K | 349.30K | 614.90K | 614.70K | 370.80K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 286.50K | 286.50K | 286.50K | 286.50K | 171.40K |
| Cash from Financing | 458.80K | 464.30K | 662.00K | 661.80K | 405.20K |
| Foreign Exchange rate Adjustments | -3.50K | 3.00K | 2.80K | -200.00 | 3.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -371.40K | 22.70K | 210.00K | 345.90K | 123.60K |